Ending the HIV Epidemic: Peer-supported collaborative care for mental health and substance use disorder care integration into HIV care settings

结束艾滋病毒流行：同伴支持的心理健康协作护理和药物滥用障碍护理纳入艾滋病毒护理机构

• 批准号: 10400376
• 负责人: Oluwaseun Falade-Nwulia
• 金额: $ 2.11万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10400376
• 关键词: Adoption; Anti-Retroviral Agents; Award; Caring; Case Manager; Characteristics; Clinic; Clinical Data; Cost Analysis; Effectiveness; Epidemic; Evidence based treatment; Grain; Group Meetings; HIV; Hybrids; Internships; Intervention; Knowledge; Maintenance; Mediator of activation protein; Medication Management; Mental Health; Mental disorders; Methods; Modeling; Outcome; Parents; Patient Recruitments; Patients; Pharmaceutical Preparations; Primary Health Care; Process; Provider; Psychiatric therapeutic procedure; Psychiatry; Questionnaires; RNA; Randomized; Reach, Effectiveness, Adoption, Implementation, and Maintenance; Research; Research Activity; Self Management; Services; Specialist; Structure; Substance Use Disorder; Supervision; Surveys; Time; Training Support; Viral; Viral Load result; addiction; care providers; collaborative care; cost; effectiveness implementation trial; evidence base; experience; implementation measures; implementation process; implementation strategy; improved; multidisciplinary; peer; peer support; randomized trial; screening; skills; substance use; treatment as usual; treatment program; trial comparing; undergraduate student

Project Abstract Despite the effectiveness of antiretroviral medications for HIV suppression, people with HIV who also have mental health and or substance use disorders suffer disparities in rates of HIV suppression and retention in HIV care. Evidence based treatment for mental health disorders (MHD) and substance use disorders (SUD), including use of medications and self-management support have been associated with improved engagement in HIV care. However, a key gap in many HIV care settings is an inability to consistently screen and provide treatment for MHD/SUD. Barriers include limited provider knowledge of, and comfort with, MHD/SUD screening and treatment; time constraints; and absence of support staff to facilitate linkage and retention in MHD/SUD care. We propose a Hybrid Type 1 implementation- effectiveness trial of an adapted collaborative care model with peer-specialists as care managers, to enhance screening and treatment for MHD/SUD with resultant improvement in rates of HIV viral suppression and care engagement in an HIV clinic setting. Collaborative care (CC), the use of a care manager/team to facilitate and coordinate integration of mental health and substance use services with primary care, is a well-established evidence-based model. We intend to adapt CC by training and supporting peer specialist to function as care managers. We will then rigorously evaluate peer-supported CC as a component of a multidisciplinary team including the HIV care provider and an addiction psychiatry consultant as an implementation strategy for MHD/SUD screening and treatment in a continuity HIV care practice. We will compare this peer-supported CC to usual care (UC) referral to psychiatric care or a SUD treatment program at the discretion of the primary care provider and evaluate the implementation process using the RE-AIM framework. Our specific aims are as follows Specific Aim 1: In a randomized trial, compare the proportion of patients with MHD/SUD with HIV suppression randomized to the collaborative care (CC) and the usual care (UC) referral strategy. We will randomize 400 patients 1:1 to CC versus UC and compare the proportion of patients with HIV suppression (defined as HIV RNA <200 copies/ml) at 12 months. Specific Aim 2: Characterize processes of CC implementation including reach, adoption, fidelity, and provider acceptability, maintenance over time, and costs associated with the approach. We propose a mixed methods approach to measure the implementation processes guided by the RE-AIM Framework. In sub Aim 2b, we will conduct a cost analysis for the peer-supported CC model. Specific Aim 3: Determine the mediators of the CC intervention on HIV viral load suppression and retention in care. We will utilize a structured questionnaire and clinical data to assess mediators of the CC intervention on HIV outcomes and qualitatively assess overall experiences with the peer supported CC model and explore if patient characteristics impact experience.

项目摘要 尽管抗逆转录病毒药物对抑制艾滋病毒有效，但艾滋病毒携带者也有 精神健康和/或物质使用障碍在艾滋病毒抑制和滞留方面存在差异 爱滋病护理。精神健康障碍(MHD)和物质使用障碍(SUD)的循证治疗， 包括使用药物和自我管理支持都与提高敬业度有关 在爱滋病护理方面。然而，许多艾滋病毒护理环境中一个关键差距是无法始终如一地进行筛查和提供 MHD/SUD的治疗。障碍包括提供商对MHD/SUD筛查的了解和熟悉程度有限 和治疗；时间限制；缺乏支助人员，以促进MHD/SUD的联系和保留 关心。我们提出了一项适应性协作护理的混合型1实施-有效性试验 以同行专家为护理经理的模式，以加强MHD/SUD的筛查和治疗 艾滋病毒诊所环境中艾滋病毒病毒抑制率和护理参与率的结果改善。 协作性护理(CC)，使用护理经理/团队来促进和协调心理整合 提供初级保健的健康和物质使用服务，是一种行之有效的循证模式。我们打算 通过培训和支持同行专家担任护理经理来适应CC。然后我们将严格执行 将同行支持的CC作为多学科团队的一部分进行评估，包括艾滋病毒护理提供者和 成瘾精神病学顾问作为MHD/SUD筛查和治疗的实施策略 连续性艾滋病毒护理实践。我们会将这种同伴支持的CC与普通护理(UC)转诊到精神病患者进行比较 由初级保健提供者酌情决定护理或SUD治疗计划，并评估 使用RE-AIM框架的实施过程。我们的具体目标如下 具体目标1：在一项随机试验中，比较患有MHD/SUD患者与HIV患者的比例 抑制随机分为协作性护理(CC)和常规护理(UC)转诊策略。我们会 将400名患者1：1随机分为CC和UC，比较HIV抑制患者的比例 (定义为HIV RNA&lt；200拷贝/毫升)。 具体目标2：描述CC实施的过程，包括REACH、采用、保真度和 供应商可接受性、随时间推移的维护以及与该方法相关的成本。我们提出了一个 混合方法方法，以衡量RE-AIM框架指导的实施过程。在子分区中 目的2b，我们将对对等支持的CC模式进行成本分析。 具体目标3：确定CC干预抑制HIV病毒载量和 留守在看护中心。我们将利用结构化问卷和临床数据来评估CC的介体 对艾滋病毒结局的干预，并定性评估同行支持的CC模型的总体体验 并探索患者特征是否会影响体验。